Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | USP2 | O75604 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638873 | 0.89 | CHRNB2 (0.55) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1556831 | 0.82 | CHRNB2 (0.60) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL20468861 | 0.82 | ALDH1A1 (0.50) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL20468876 | 0.81 | ALDH1A1 (0.47) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL2834740 | 0.81 | CYP3A4 (0.68) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL6231833 | 0.81 | CHRNB2 (0.46) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| Hydrochloric Acid SCHEMBL485785 | 0.80 | CYP3A4 (0.67) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1556724 | 0.79 | CHRNB2 (0.61) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL20468877 | 0.78 | CYP2D6 (0.44) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 | |
| SCHEMBL1556624 | 0.78 | ALDH1A1 (0.44) | CYP2D6ALDH1A1CYP3A4USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519939-B9 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2011-04-06 | — | — | EP | claimed |
| EP-1519939-B1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | claimed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | claimed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | claimed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | claimed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | disclosed |
| WO-2018141984-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018141984-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-09 | — | — | WO | disclosed |
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7923559-B2 | 7-(3-pyridyl)-1,7-diazaspiro[4.4]nonane; mania, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, Tourette's syndrome | TARGACEPT, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1519939-B9 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1784184-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | Targacept, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | BHATTI BALWINDER S | 2006-09-28 | — | — | US | disclosed |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | BHATTI BALWINDER S | 2006-03-16 | — | — | US | disclosed |
| WO-2006023630-A2 | THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION | TARGACEPT, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | BHATTI BALWINDER S | 2005-12-08 | — | — | US | disclosed |
| US-6956042-B2 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TARGACEPT, INC. | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105548-A1 | N-ARYL DIAZASPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | CYP2D6 44/4885ALDH1A1 1667/4885CYP3A4 125/4885 |
| US-20200048267-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | CYP2D6 4092/4885ALDH1A1 3839/4885CYP3A4 4278/4885 |
| US-20060217406-A1 | N-ARYL DIAZASPIRACYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TNNC1, ACHE, CHRNA6 | CYP2D6 37/4885ALDH1A1 1337/4885CYP3A4 140/4885 |
| US-20050272739-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CYP2D6 37/4885ALDH1A1 1337/4885CYP3A4 140/4885 |
| US-20060058328-A1 | Use of N-aryl diazaspiracyclic compounds in the treatment of addiction | OPRD1, OPRK1, OPRL1 | CYP2D6 40/4885ALDH1A1 1126/4885CYP3A4 105/4885 |
| US-20040067930-A1 | N-aryl diazaspiracyclic compounds and methods of preparation and use thereof | TNNC1, ACHE, CHRNA6 | CYP2D6 37/4885ALDH1A1 1337/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.